J. Catalano

发表

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Christian Jacques, Nizar Bahlis, Michele Cavo, 2014, The New England journal of medicine.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

A. Berrebi, H. Döhner, G. Fingerle-Rowson, 2010, The Lancet.

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

A. Hagenbeek, G. Salles, A. López-Guillermo, 2013 .

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, British journal of haematology.

domain mutations identify imatinib-treated patients with CML who have BCR-ABL kinase Real-time quantitative PCR analysis can be used as a primary screen to

R. Herrmann, P. Browett, A. Schwarer, 2012 .

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

R. Herrmann, P. Browett, A. Schwarer, 2004, Blood.

A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma.

J. Zeldis, J. Bladé, S. Rajkumar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

A. Shields, H. Kantarjian, S. Verstovsek, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

P. Ganly, T. Robak, C. Geisler, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

L. Sehn, B. Coiffier, M. Pfreundschuh, 2014, Haematologica.

Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised , open-label , phase 3 trial

G. Fingerle-Rowson, M. Hallek, M. Hensel, 2010 .

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

T. Barbui, J. Dipersio, M. Arcasoy, 2014, Haematologica.

Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group

J. Reynolds, D. Goldstein, D. Joseph, 2011, Leukemia & lymphoma.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

M. Beksac, M. Dimopoulos, W. Wiktor-Jedrzejczak, 2012, The New England journal of medicine.

Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.

A. Palumbo, R. Hájek, M. Delforge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2011 .

and FCGR3A chemoimmunotherapy in the PRIMA study is not affected by Clinical outcome of patients with follicular lymphoma receiving

F. Jardin, G. Salles, R. Bouabdallah, 2014 .

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

F. Jardin, G. Salles, R. Bouabdallah, 2012, Blood.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR 3 A and FCGR 2 A polymorphisms

F. Jardin, G. Salles, R. Bouabdallah, 2012 .

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

R. Mesa, D. Mclornan, J. Gotlib, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

J. Dipersio, M. Arcasoy, H. Kantarjian, 2017, Journal of Hematology & Oncology.

PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study

M. Dimopoulos, R. Foà, A. Palumbo, 2013 .

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.

D. Tait, D. Cunningham, C. Tiley, 1992, Leukemia & lymphoma.

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

J. Reynolds, L. Chong, P. Browett, 2012, Haematologica.

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms

R. Lea, M. Gandhi, P. Marlton, 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

M. Dimopoulos, M. Mohty, J. Cavenagh, 2018, Blood.

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

H. van de Velde, H. Prince, S. Harrison, 2015, American journal of hematology.

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

T. Kipps, W. Cosolo, E. Punnoose, 2015, Leukemia & lymphoma.

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma

M. Dimopoulos, R. Foà, M. Delforge, 2009 .

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

M. Dimopoulos, R. Hájek, M. Delforge, 2010 .

Appearance of del(11q) in two patients with acute promyelocytic leukaemia treated with all‐trans retinoic acid and combination chemotherapy

L. Campbell, J. Catalano, J. Catalano, 2002, British journal of haematology.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point

M. Dimopoulos, A. Palumbo, R. Foà, 2015, Haematologica.

Haematological Effects of Betamethasone Treatment in Late Pregnancy

E. Wallace, J. Catalano, C. Tippett, 1998, The Australian & New Zealand journal of obstetrics & gynaecology.

Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.

R. Marcus, D. Cunningham, A. Belch, 2005 .

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

R. Yeh, O. Spleiss, D. Dornan, 2009 .

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

P. Ganly, T. Robak, C. Geisler, 2008 .

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

A. Berrebi, U. Jaeger, H. Döhner, 2008 .

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

A. Hagenbeek, G. Salles, A. López-Guillermo, 2010 .

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

G. Salles, A. López-Guillermo, B. Coiffier, 2017 .

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2005, Blood.

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.

W. Hofmann, A. Ho, J. Szer, 2006, Blood.

acute myeloid leukemia: results of a randomized phase III trial immunotherapy with histamine dihydrochloride and interleukin-2 in Improved leukemia-free survival after post-consolidation

W. Hofmann, A. Ho, J. Szer, 2013 .

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

R. Greil, P. Gaulard, G. Salles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour lysis following hydrocortisone prior to a blood product transfusion in T-cell acute lymphoblastic leukaemia.

D. Grimwade, C. Tiley, R. Powles, 1992, Leukemia & lymphoma.

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

W. Hiddemann, R. Yeh, S. Bohlander, 2013, Blood.

Inactivation of TP 53 correlates with disease progression and low miR-34 a expression in previously treated chronic lymphocytic leukemia patients

W. Hiddemann, R. Yeh, S. Bohlander, 2013 .

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma

V. Ganju, A. Roberts, L. Mileshkin, 2005, Clinical Cancer Research.

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.

J. Szer, J. Matthews, A. Schwarer, 2005, Blood.

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

J. Zeldis, J. Bladé, S. Rajkumar, 2006 .

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

G. Salles, A. López-Guillermo, L. Xerri, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

R. Marcus, A. Dmoszyńska, P. Solal-Céligny, 2006 .

Effect of FCGR2A and FCGR3A variants on CLL outcome.

R. Yeh, O. Spleiss, D. Dornan, 2010, Blood.

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

R. Yeh, H. Döhner, M. Hallek, 2014, Blood.

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

M. Dimopoulos, J. Cavenagh, A. Dispenzieri, 2013 .

Effect of FCGR2Aand FCGR3Avariants on CLL outcome

R. Yeh, O. Spleiss, D. Dornan, 2017 .

Effect of FCGR 2 A and FCGR 3 A variants on CLL outcome

R. Yeh, O. Spleiss, D. Dornan, 2010 .

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2003 .

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

R. Greil, P. Gaulard, B. Coiffier, 2019, British journal of haematology.

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

W. Jędrzejczak, S. Rajkumar, J. Zeldis, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

R. Hills, A. Wei, A. Burnett, 2010 .

No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation.

C. Tiley, R. Powles, J. Catalano, 1992, Bone marrow transplantation.

A multicenter phase 2 study of risk‐adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma

J. Catalano, A. Grigg, C. Arthur, 2008, Cancer.

A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study)

M. Gandhi, P. Marlton, J. Catalano, 2014, British journal of haematology.

Bioflora Probiotic in Immunomodulation and Prophylaxis of Intestinal Bacterial Translocation in Rats

J. Catalano, P. Miguel, P. San Miguel, 2008, Digestive Diseases and Sciences.

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013 .

Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.

A. Wei, S. Fleming, A. Schwarer, 2017, Oncotarget.

Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial

M. Dimopoulos, R. Foà, A. Palumbo, 2012 .

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

M. Dimopoulos, A. Belch, D. Reece, 2015 .

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

J. Dipersio, H. Kantarjian, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM)

M. Dimopoulos, A. Palumbo, R. Hájek, 2010 .

Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

A. Wei, A. Schwarer, S. Avery, 2010 .

Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia.

J. Mehta, D. Catovsky, C. Tiley, 1993, Bone marrow transplantation.

AMulticenter Phase II TrialofThalidomide andCelecoxib for Patients with Relapsed and RefractoryMultipleMyeloma

V. Ganju, A. Roberts, J. Zeldis, 2005 .

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

W. Hofmann, A. Ho, J. Szer, 2004 .

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

W. Hiddemann, S. Bohlander, K. Spiekermann, 2010 .

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

R. Yeh, H. Döhner, M. Hallek, 2014, Blood.

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

G. Salles, L. Sehn, A. Zelenetz, 2016 .

Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia

R. Hills, A. Wei, J. Catalano, 2018, Leukemia & lymphoma.